Table 5.

Rates of thromboembolic events, cataracts, and cataracts surgery—NSABP STAR Trial (P-2)

Type of eventEvents, nRate per 1,000RR*RR (95% CI)
TamoxifenRaloxifeneTamoxifenRaloxifeneDifference
Thromboembolic events2021543.302.470.830.750.60–0.93
    Pulmonary embolism84681.361.090.270.800.57–1.11
    Deep-vein thrombosis118861.931.380.550.720.54–0.95
Cataracts and Cataract Surgery
Developed cataracts during follow-up73960314.5811.692.890.800.72–0.89
Developed cataracts and had cataract surgery57546211.188.852.330.790.70–0.90

Abbreviations: CI, confidence interval; NSABP STAR, National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene; RR, risk ratio.

  • *Risk ratio for women in the raloxifene group compared to women in the tamoxifen group.

  • Rate in the tamoxifen group minus rate in the raloxifene group.

  • Women at risk were those with no prior history of cataracts at entry (8,341 and 8,336 tamoxifen and raloxifene participants, respectively).